Could tailoring chemo by age make stem cell transplants safer for MDS patients?
NCT ID NCT07677306
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study looks at two different chemotherapy combinations given before a half-matched stem cell transplant in adults with myelodysplastic syndrome (MDS). One regimen is designed for people aged 55 and older to reduce side effects, while the other is a standard stronger regimen for younger patients. The goal is to see which approach leads to fewer deaths related to the transplant itself within the first year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
busulfan, cytarabine, cyclophosphamide, fludarabine, semustine, antithymocyte globulin
What this could lead to
If successful, this could help tailor chemotherapy doses before transplant to lower the risk of death from the procedure for people with myelodysplastic syndrome.
What could go wrong
This is a mid-stage study with 120 participants, so results may not apply to all patients. Chemotherapy before transplant can cause serious side effects like organ damage and infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital, Beijing Lu Daopei Hematology Hospital, Hebei Yanda Lu Daopei Hospital, Nanfang Hospital, Southern Medical University
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••